CRH Medical Corp (CRHM) EPS Estimated At $0.04

July 18, 2017 - By Henry Gaston

 CRH Medical Corp (CRHM) EPS Estimated At $0.04

Analysts expect CRH Medical Corp (NYSEARCA:CRHM) to report $0.04 EPS on July, 27.They anticipate $0.02 EPS change or 100.00 % from last quarter’s $0.02 EPS. CRHM’s profit would be $2.69 million giving it 22.81 P/E if the $0.04 EPS is correct. After having $0.02 EPS previously, CRH Medical Corp’s analysts see 100.00 % EPS growth. The stock decreased 2.67% or $0.1 during the last trading session, reaching $3.65. About 28,530 shares traded or Infinity% up from the average. CRH Medical Corp (NYSEARCA:CRHM) has risen 97.28% since July 18, 2016 and is uptrending. It has outperformed by 80.58% the S&P500.

CRH Medical Corporation is a Canada healthcare services and products company. The company has market cap of $245.79 million. The Firm focused on providing physicians with services and products for the treatment of gastrointestinal diseases. It has a 73 P/E ratio. The Firm also provides anesthesiology services to gastroenterologists in the United States through its subsidiaries.

More notable recent CRH Medical Corp (NYSEARCA:CRHM) news were published by: Prnewswire.com which released: “CRH Medical Corporation Comments on the Centers for Medicare and Medicaid …” on July 17, 2017, also Prnewswire.com with their article: “CRH Medical Corporation Announces Majority Purchase of an Anesthesia Practice …” published on February 01, 2017, Benzinga.com published: “Analyst: Buy CRH Medical After An ‘Overdone’ Selloff” on July 17, 2017. More interesting news about CRH Medical Corp (NYSEARCA:CRHM) were released by: Prnewswire.com and their article: “CRH Medical Corporation To Announce Unaudited Q1 2017 First Quarter Results on …” published on April 18, 2017 as well as Seekingalpha.com‘s news article titled: “CRH Medical’s (CRHM) CEO Edward Wright on Q4 2016 Results – Earnings Call …” with publication date: February 26, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.